Chief Executive Officer

Size: px
Start display at page:

Download "Chief Executive Officer"

Transcription

1 Said Darwazah Chief Executive Officer

2 211 highlights Strong Group performance in a challenging year 95 9 MSI PROMOPHARM $11.2 m $918.m BRANDED + 9.6% $37.9 m INJECTABLES % $36.7 m GENERICS % $19.7 m OTHER $.1m $786.6m $12.3 m 7 $73.9m Group Revenue Branded Injectables Generics Others 211 Organic Revenue MSI Promopharm 211 Group Revenue Page 1

3 Khalid Nabilsi Chief Financial Officer

4 Consolidated P&L Strong Group performance in a challenging g year $ million Change Revenue % Gross profit % Gross margin 43.1% 48.9% Operating profit % Adjusted 1 operating profit % Adjusted operating margin 15.9% 19.6% -3.7 Adjusted 2 net income % Basic EPS (cents) % Adjusted diluted EPS (cents) % Dividend per share (cents) Effective tax rate 11.1% 17.7% Page 3 1 Before the amortisation of intangible assets (excluding software) and exceptional items (including acquisition and integration costs of $16.4 million and an inventory adjustment of $1.8 million) 2 Before the amortisation of intangible assets (excluding software) and exceptional items

5 Branded Robust growth, despite the Arab Spring disruptions Revenue ($ million) 5 Organic 1 growth of 9.6%, ahead of 7% guidance % growth + 9.6% organic growth Egypt and Tunisia back to normal and recovery beginning in Libya Good growth across other key MENA markets Algeria, Sudan, Jordan, GCC 25 2 Successful completion of strategic acquisition in Morocco 15 1 Strengthened manufacturing capacity and capabilities in Sudan, Algeria, Egypt and Tunisia Page 4 1 Before the Promopharm acquisition

6 Branded Relatively stable operating margin despite inflationary pressure in MENA Gross profit ($ million) % Gross margin Change Reported 51.6% 48.4% Adjusted operating profit ($ million) % Operating margin Change Reported 25.% 22.3% Adjusted % 23.8% -.6 Page 5 1 Before the amortisation of intangible assets (excluding software) and exceptional items

7 Injectables Doubled Injectables sales to $316 million, with strong growth across all markets Injectables revenue by region ($ million) $ MSI MSI % % +14.2% $75.4 Promopharm USA Europe MENA Page 6

8 Injectables Excellent e improvement e in operating margin Gross profit ($ million) Adjusted operating profit ($ million) % % % 85. Injectables incl. MSI Injectables ex MSI % Injectables incl. MSI Injectables ex MSI Gross margin Change Reported 45.1% 4.4% Operating margin Change Reported 15.1% 14.4% -.7 Adjusted % 17.4% +.7 Organic % 17.5% Page 7 1 Before the amortisation of intangible assets (excluding software) and exceptional items 2 Before the MSI and Promopharm acquisitions

9 Generics Sales of $155 million, in line with guidance Revenue ($ million) 2 Reported sales declined by 11.3% % Excluding exceptional colchicine sales in 21, Generics achieved double-digit revenue growth in Strong volume growth was partially offset by accelerating pricing pressure Page 8

10 Generics Margin decline reflects exceptional benefit of colchicine sales in 21 Gross profit ($ million) Adjusted operating profit ($ million) % % Gross margin Change Reported 46.9% 33.7% Operating margin Change Reported 29.3% 11.% Adjusted % 11.1% 1% Page 9 1 Before the amortisation of intangible assets (excluding software)

11 Cash Flow Strong management of working capital Operating cash flow ($ million) 18 Group operating cash flow was $147.5 million, excluding the $21.1 million impact of the working capital financing for the MSI acquisition ex MSI 211 incl MSI Change Receivable days** (3) Inventory days (29) Payable days (12) Working capital days ** (2) 6 4 Operating Cash Flow / Sales 2.9% 16.1% 13.8% (7.1) 2 21 * 211 Page 1 * Group operating cash flow in the 21 Annual Report of $144.8 million has been adjusted to $152.5 million to exclude acquisition costs of $7.7 million in 21 and reclassify these within investing activities ** Certain items included within trade receivables in the 21 Annual Report have been reclassified. The calculations of receivable days and working capital days for 21 reflect these reclassifications

12 Capital expenditure Increased capex to support Branded and Injectables growth Capital expenditure ($ million) 8 Expansion of our manufacturing capacity and capabilities in MENA Algeria, Egypt and Tunisia % Machinery and equipment for our new lyophilisation facility in Portugal Investment in machinery and equipment for our MSI business MENA Europe US Page 11

13 Balance sheet Solid balance sheet after investments of $325 million in 211 Net debt position at 31 December 211 ($ million) Short-term borrowing Net debt Net debt/ebitda 2.55x.58x Net debt/equity.54x.14x Long-term borrowing Cash & cash equivalents Page 12

14 Summary Positive outlook for 212 Group revenue growth of around 2% Increased investment in R&D to be around 4.5% of Group sales Group finance expense of around $32 million Capital expenditure in the range of $85 million to $9 million Effective tax rate to be around 2%, reflecting the change in geographic sales mix Page 13

15 MENA REVIEW Said Darwazah Chief Executive Officer

16 Continuing to deliver strong growth and increase MENA market share Leading pharmaceutical companies in the MENA market Rank Unit sales Vl Value Avg Rx $ Growth Market share 211 (M) $M Price % % MENA PRIVATE MARKET 3,369 9, SANOFI GLAXOSMITHKLINE NOVARTIS PFIZER HIKMA PHARMA MERCK & CO SPIMACO ASTRAZENECA ABBOTT NOVO NORDISK Page 15 Source: IMS Healthcare YTD12/211. Private retail sales for 9 top MENA markets (Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and UAE). Data excludes tender and injectables sales.

17 Despite Arab Spring, fundamental MENA growth drivers remain intact In May 211, the In December 211, interim Egyptian Saudi Arabia allocated Morocco announced the In March 211, the Jordanian Government agreed US4.4bn for investment in expansion of healthcare Government announced it to increase the the healthcare sector in assistance to benefit 8.5 had increased its social safety healthcare budget to January 212* million people** package in the 211 budget 11% of total by US$65m* expenditure* 21 YTD growth 3.% 211 YTD growth 25.% 2.% 15.% 1.% 5.%.% -5.% Egypt KSA Algeria Morocco UAE Lebanon Tunisia Jordan Kuwait MENA Page 16 Source: IMS Healthcare YTD12/211 and YTD 12/21. * Business Monitor International ** Epsicom Business Intelligence

18 Investment in facilities and people strengthens our MENA operations Morocco Total sales reps by country at December 211 Acquired local manufacturing facility Added 137 sales reps Added 22 products* Algeria Completed and inaugurated a new penicillin facility Tunisia Completed facilities upgrades to increase capacity and efficiency i Morocco 137 Tunisia 56 Algeria 186 Libya 28 Lebanon Jordan Egypt 44 Sudan 75 Syria 5 Iraq 42 Saudi Arabia 253 Yemen 4 Kuwait 8 Bahrain 7 & Qatar 7 UAE 5 Oman 9 Egypt Increased manufacturing capacity by 2% Sudan Acquired local manufacturing facility Added 48 products** Jordan Begun expansion of chemical facility Invested over $215 million in acquisitions and capex in MENA in 211 Page 17 * 192 of which are new products to Hikma ** 17 of which are new products to Hikma

19 Our robust business model limited the Arab Spring impact 211 revenue growth in Egypt, Tunisia and Libya Egypt and Tunisia benefitted from: 12.1% 1% Local manufacturing - Local management and sales teams - Experience of operating in politically unstable markets - Commitment to our employees (3.3%) (33.2%) Strength of our local team enabled swift re- entry into Libya Egypt Tunisia* Libya Page 18 Source: Hikma Branded and Injectables sales in 21 and 211 * Sales in 21 are proforma sales to include the full year effect of Ibn Al Baytar which was consolidated from April 21 on a reported basis

20 Growth in MENA Injectables will be driven by new product launches Targeted Injectables launches in key MENA markets, * Algeria Egypt GCC Iraq Jordan KSA Page 19 * Refers to the launch of new molecules in new markets, not including any additional launches of different dosage forms and strengths

21 Product portfolio development will be key growth driver in MENA Optimising product portfolio Focus on maximising sales of high value, high margin products Cut tail products New product launches More aggressive focus on the registration and launch of new products Identified 4 strategic molecules for fast track programme In-licensed partnerships Focus on building pipeline of products from existing in-license partners Develop new relationships and at different stages in the development process Unimark Leverage our investment in Unimark to supplement our in-house R&D activities Page 2

22 Successfully integrating Promopharm in Morocco 4th largest MENA market 8.7% growth in 211 Hikma people in place in Morocco supporting integration and business development opportunities Expected to growsales team from 137 to 2 by the end of 213 Begun work to register 2 strategic Hikma products in Morocco launch around 214 Potential MENA licensing opportunities Page 21

23 USA REVIEW

24 Injectables will be the key driver of future growth in the US US generics market value Product segment 211 Sales (value) 211 growth (%) No. of players (sales greater than $1 million) Orals $3.31bn Injectables $7.9bn Others $6.73bn +22.9% Total US Generics market $44.13bn +13.8% 48 Page 23 Source: IMS Health, National Sales Perspectives, YTD December 211

25 Developing an increasingly strong position in the US injectables market Top US generics injectables suppliers (million eaches) 6, 5, 41.2% 4, 3, 2, 17.3% 14.5% 1, 6.6% 4.2% 3.8% 3.4% 2.4% 1.4%.9%.9%.8% Page 24 Source : IMS Health MAT 12/211

26 Swift integration of the MSI business is delivering sales growth and increased profitability Headcount (FTE) Production units (millions) May % Headcount has been reduced by c.12% % Increased monthly production driven by restructuring of manufacturing processes and reorganisation of facilities Dec-11 May-11 Dec-11 Units produced per labour hour % Production cost per unit has significantly reduced as a result of headcount reductions and process efficiency improvements May-11 Dec-11 Page 25

27 Hikma s underlying US Injectables business is performing well US Injectables Total products marketed 211 US Injectables revenue excluding MSI 25 CNS Anti-infectives 15 Others, 16% Cardiovascular 13 Cardiovascular, CNS, 47% 17% Others Anti-infectives, 2% Page 26

28 Building a differentiated product pipeline to drive growth US Injectables product pipeline Pipeline ANDAs Dormant ANDAs R&D partnerships & differentiated products Products under- development Page 27

29 Increased scale of our global Injectables business is driving growth in Europe and MENA tender sales 211 Europe Injectables revenue ($ million) 9 Highly productive and efficient European facilities remain a key manufacturing hub % Portuguese facilities produce for US, Europe and MENA - New lyophilisation plant inaugurated in October Increased high value contract manufacturing opportunities in Europe - Benefiting from high quality reputation and track record of delivery 2 1 Increased scale is driving greater success in European and MENA tenders Page 28

30 Maintained market position in US oral generics market US generic oral market Orals 29 ( s) 21 ( s) 211( s) Total prescriptions written 2,49,483 2,576,24 2,76,71 Market growth +7.2% +6.9% +5.7% Hikma (West-Ward) Ward) Total prescriptions written 33,77 44,23 53,261 Growth +37.7% +3.9% +2.49% Total prescriptions written (excl. colchicine) 31,254 4,945 52,779 Growth (excl. colchicine) +32.5% +31.% +29% Hikma (West-Ward) rank Hikma (West-Ward) market share 1.4% 1.7% 1.95% Page 29 Source: IMS Health YTD December 211. Number of prescriptions filled in the US generics market for oral pharmaceuticals.

31 Short term focus on leveraging our MENA facilities. R&D investment driving future growth Percentage of Generics sales produced in MENA* US Generics product pipeline 3.% 25.% 5% 25.1% 21.2% 26.8% % 2 15.% 15 1.% 7.2% 9.4% 1 5.%.% Unimark** 2 R&D partnerships and differentiated products Pipeline ANDAs Products underdevelopment Page 3 * Oral generic products produced at our FDA approved facilities in Jordan and Saudi Arabia and sold in the US. Sales figures exclude colchicine ** Unimark brings a portfolio of potential ANDAs. We made 1 product submission in 211. We will begin the process for selecting additional submissions in 212.

32 CONCLUSION

33 Conclusion Group revenues ($ million) Acquired Baxter s Multi Source Injectables (US) in May 211 Acquired minority stake in Unimark (India) and Haosun (China) Acquired 94.1% of Promopharm in Morocco Acquired Elie Pharmaceuticals in Sudan Inauguration of Dar Al Arabia in Algeria HIKMA established in Jordan. Licenses from Fujisawa Japan Acquired Ibn Al Baytar/ Medicef In Tunisia Acquired Al Dar Al Arabia in Algeria Began manufacturing operations in Trust Pharma Algeria. Acquisition of the 52.5% of JPI not previously owned dby Hikma West-ward (US) acquired Hikma Farmaceutica (Portugal) established Started operations at Jazeera Pharmaceutical Industries (JPI) in Saudi Arabia) Acquired Ribosepharm and Thymoorgan (Germany) in H1 27. Acquired Alkan (Egypt) and APM (Jordan) in H2 27. Became public company listed on LSE. Acquired Hikma Italy. Hikma Pharma (Holding Co) established in Jersey. Acquired majority interest in clinical pharma research lab (IPRC) Page 32

34 Appendix

35 Revenue by segment and region 211 revenue by segment 211 revenue by region 48.1% 55.4% 16.9% 34.6%.6% 34.4% 1.% Branded Generics Injectables Other MENA US Europe & ROW Page 34

36 Injectables sales by region 211 Injectables revenue by region 51.4% 23.9% 24.8% MENA US Europe & ROW Page 35

37 Cash flow statement $ million Profit before tax and minority interest Adjustments for non-cash items Change in working capital (54.7) 4.7 Income tax paid (2.1) (32.7) Other Net cash generated from operating activities Investment in property, plant and equipment (69.) (49.1) Purchase of intangible assets (9.) (4.1) Acquisition of subsidiaries (217.8) (23.) Investment in associated companies (38.6) - Interest received.5.3 Other (9.6) (16.2) Net cash used in investing activities (343.5) (92.1) Issuance of new shares Change in debt (26.6) Dividends paid (25.2) (23.1) Interest paid (23.8) (13.8) Other (27.8) (1.1) Net cash generated from financing activities (61.2) Page 36

38 Balance sheet $ million Growth $ Growth % Cash % Trade and other receivables % Other current assets >119% Inventories % Total current assets % Intangible assets % Tangible fixed assets % Investment in associated companies and joint ventures >2% Other long-term assets % Total long-term assets % Total assets 1,576 1, % Financial debts and capital lease obligations % Trade accounts payable % Other current liabilities % Total current liabilities % Long-term financial debts and capital lease obligations >2% Other long-term liabilities % Total long-term liabilities >2% Total liabilities % Minority interest >2% Total shareholders equity % Total liabilities and shareholders equity 1,576 1, % Page 37

39 Branded Launching new products and developing markets Product launches in 211 Product approvals in MENA & ROW 1 1 Europe 3 5 MENA & ROW Europe New compounds New dosage forms and strengths Total product tlaunches New compounds New dosage forms and strengths Total product approvals Page 38

40 Branded Pipeline for future growth Product submissions in 211 Pending approvals in MENA & ROW Europe 5 MENA & ROW 3 4 Europe 14 New compounds New dosage forms and strengths Total submissions i New compounds New dosage forms and strengths Total pending approvals Page 39

41 Injectables Launching new products and developing new markets Product launches in 211 Product approvals in US MENA & ROW Europe US MENA & ROW Europe New compounds New compounds New dosage forms and strengths New dosage forms and strengths Total product tlaunches Total product approvals Page 4

42 Injectables Pipeline for future growth Product submissions in 211 Pending approvals in US MENA & ROW Europe US MENA & ROW Europe New compounds New dosage forms and strengths Total submissions i New compounds New dosage forms and strengths Total pending approvals Page 41

43 Generics Launching new products 1 Product launches in 211 Product approvals in US US New compounds New compounds New dosage forms and strengths Total product tlaunches New dosage forms and strength Total product approvals Page 42

44 Generics Pipeline for future growth Product submissions in 211 Pending approvals in US US New compounds New dosage forms and strengths Total submissions i New compounds New dosage forms and strengths Total pending approvals Page 43

HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007

HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007 HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007 About Hikma Founded in Jordan in 1978 Multinational business developing, manufacturing and marketing

More information

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC This document, which has been issued by Hikma Pharmaceuticals PLC (the Company ), comprises the written materials/slides for a presentation. This document and its contents are

More information

Current trends in generic medicines in the Middle East: challenges and opportunities. Mazen Darwazah Vice Chairman, Hikma Pharmaceuticals PLC

Current trends in generic medicines in the Middle East: challenges and opportunities. Mazen Darwazah Vice Chairman, Hikma Pharmaceuticals PLC Current trends in generic medicines in the Middle East: challenges and opportunities Mazen Darwazah Vice Chairman, Hikma Pharmaceuticals PLC Middle East and North African pharmaceutical markets Middle

More information

Hikma Pharmaceuticals PLC. Meet the Management Day 15 November 2016

Hikma Pharmaceuticals PLC. Meet the Management Day 15 November 2016 Hikma Pharmaceuticals PLC Meet the Management Day 15 November 2016 This document, which has been issued by Hikma Pharmaceuticals PLC (the Company ), comprises the written materials/slides for a presentation.

More information

Better health. Within reach. Every day.

Better health. Within reach. Every day. Better health. Within reach. Every day. v Hikma Pharmaceuticals PLC 2018 Interim Results Hikma Pharmaceuticals PLC Group 1H18 financial highlights $989m $214m 21.6% 61.4 $185m Revenue Core 1 operating

More information

Overview. Highlights. Financial highlights

Overview. Highlights. Financial highlights Injectables Our Injectables business manufactures, markets and sells generic injectable products in the US, the MENA region and Europe. In the US, we are the third largest manufacturer of injectables by

More information

Our core lies in quality, performance and courage

Our core lies in quality, performance and courage Our core lies in quality, performance and courage Tabuk Pharmaceuticals develops, manufactures, markets and distributes branded generic pharmaceuticals and under-licensed products globally, with a strong

More information

Hikma s diversified business delivers record sales and 36% earnings growth in 2009

Hikma s diversified business delivers record sales and 36% earnings growth in 2009 PRESS RELEASE Hikma s diversified business delivers record sales and 36% earnings growth in 2009 17 March 2010 ( Hikma ) (LSE: HIK) (NASDAQ DUBAI: HIK), the fast growing multinational pharmaceutical group,

More information

Hikma Pharmaceuticals PLC Annual Report A strategy for growth

Hikma Pharmaceuticals PLC Annual Report A strategy for growth Hikma Pharmaceuticals PLC Annual Report 2005 A strategy for growth Hikma Pharmaceuticals PLC Contents 02 Group at a glance 04 Chairman and Chief Executive s review 06 Our strengths 14 Business and financial

More information

HIKMA PHARMACEUTICALS (HIK)

HIKMA PHARMACEUTICALS (HIK) HIKMA PHARMACEUTICALS (HIK) Equity Research Report H1 2009 Results Update P.O. Box 930059, Amman 11193, Jordan Tel. + 962 (0) 6 5629300, Fax. + 962 (0) 6 5682941 www.abci.com.jo (A wholly owned subsidiary

More information

Constant currency numbers in 2016 represent reported 2016 numbers re-stated using average exchange rates in

Constant currency numbers in 2016 represent reported 2016 numbers re-stated using average exchange rates in PRESS RELEASE Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency London, 15 March 2017

More information

Introduction to KUWAIT

Introduction to KUWAIT Introduction to KUWAIT Kuwait is the world s 10th largest producer of oil. Total oil production, which is equivalent to half the country s GDP, was estimated at 2.9 million barrels per day in 2016. Oil

More information

BUILDING FOR THE FUTURE. Hikma Pharmaceuticals PLC Annual Report 2016

BUILDING FOR THE FUTURE. Hikma Pharmaceuticals PLC Annual Report 2016 BUILDING FOR THE FUTURE Hikma Pharmaceuticals PLC Annual Report 2016 Contents Strategic report Overview IFC / At a glance Our business 2 / Chairman and Chief Executive s statement 4 / Our investment case

More information

Introduction to SAUDI ARABIA

Introduction to SAUDI ARABIA Introduction to SAUDI ARABIA Saudi Arabia is the world s largest oil producer and exporter with almost one-fifth of the word s proven oil reserves. Benefiting from abundant and cheap energy, the industrial

More information

Hikma reports 2017 full year results

Hikma reports 2017 full year results Press Release Hikma reports full year London, 14 March 2018 Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody s / BB+ S&P, both stable), the multinational

More information

Introduction to MOROCCO

Introduction to MOROCCO Introduction to MOROCCO With a GDP of USD 101bn in 2015, Morocco is a medium-sized economy. Sound macroeconomic fundamentals, a resilient and sophisticated banking sector and the implementation of structural

More information

Investor Relations Presentation December 2012

Investor Relations Presentation December 2012 Investor Relations Presentation December 2012 Contents 1. QNB at a Glance 2. QNB Comparative Positioning Qatar and MENA 3. Financial Highlights December 2012 4. Economic Overview 2 QNB at a Glance QNB

More information

Dr. Raja M. Almarzoqi Albqami Institute of Diplomatic Studies

Dr. Raja M. Almarzoqi Albqami Institute of Diplomatic Studies Dr. Raja M. Almarzoqi Albqami Institute of Diplomatic Studies Rmarzoqi@gmail.com 3 nd Meeting of OECD-MENA Senior Budget Officials Network Dubai, United Arab Emirates, 31 October-1 November 2010 Oil Exporters

More information

Hikma delivers stable profitability and strong cash generation in H1 and maintains a solid balance sheet

Hikma delivers stable profitability and strong cash generation in H1 and maintains a solid balance sheet The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this

More information

Working Group 1. Session 2: International Investment Agreements

Working Group 1. Session 2: International Investment Agreements Working Group 1 Session 2: International Investment Agreements 4 September 2007, Amman Dr. Alexander Böhmer OECD, Directorate for Financial and Enterprise Affairs What is the purpose of international investment

More information

Rising Middle East Stock Markets

Rising Middle East Stock Markets Rising Middle East Stock Markets Index, January 2002 = 100 1400 1200 1000 800 600 400 200 Egypt Israel Jordan Kuwait Saudi Arabia U.A.E. 0 2003 2004 2005 2006 Source: Bloomberg Capital Access Index 2006

More information

Registration Insights & Pricing Structure Across The MENA Region. Mr Yahya A. Al jefri. CEO, Annahdah Medical Company, Saudi

Registration Insights & Pricing Structure Across The MENA Region. Mr Yahya A. Al jefri. CEO, Annahdah Medical Company, Saudi 1 Registration Insights & Pricing Structure Across The MENA Region 10-2017 Mr Yahya A. Al jefri. CEO, Annahdah Medical Company, Saudi AMC company profile 2 AMC establishment 3 Established in 1971, AMC

More information

Hikma reports strong 2018 interim results and raises full year guidance

Hikma reports strong 2018 interim results and raises full year guidance Press Release Hikma reports strong 2018 interim and raises full year guidance London, 15 August 2018 Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody

More information

First Half Results 2008:

First Half Results 2008: First Half Results 2008: A strong performance in the first half ALMA gaining momentum August 4 th, 2008 First half results 2008 Agenda A strong performance in the first half ALMA gaining momentum John

More information

Introduction to TUNISIA

Introduction to TUNISIA Introduction to TUNISIA Tunisia is small open economy with strong ties to Europe. The country has been cited as a success story for a number of years, following decades of robust growth and impressive

More information

NORTH AFRICA HOLDING COMPANY

NORTH AFRICA HOLDING COMPANY NORTH AFRICA HOLDING COMPANY Unlocking Potential Creating Value CORPORATE PRESENTATION December 2010 1 Agenda North Africa Holding Company Why investing in North Africa KIPCO Group 2 Snapshot on North

More information

MENA Benchmarking Report Arab-EU Business Facilitation Network

MENA Benchmarking Report Arab-EU Business Facilitation Network MENA Benchmarking Report Arab-EU Business Facilitation Network www.ae-network.org September 2014 Agenda Objective of the Report Macroeconomic Analysis Business Environment Index MENA Rankings 2 Objective

More information

Improving the Business Environment in Iraq Through Secured Transactions

Improving the Business Environment in Iraq Through Secured Transactions Improving the Business Environment in Iraq Through Secured Transactions Murat Sultanov Beirut, October 17, 2011 CONTENTS What is Secured Transactions? Economic Importance 1 Why these systems are underdeveloped

More information

Re-assessing the Arab-European Financial Relationship: Continuity in the Middle East, Change in Europe

Re-assessing the Arab-European Financial Relationship: Continuity in the Middle East, Change in Europe Re-assessing the Arab-European Financial Relationship: Continuity in the Middle East, Change in Europe Andrew Cunningham Founder Darien Middle East www.darienmiddleeast.com French-Arab Banking Dialogue

More information

Akorn, Inc. N a s d a q : A K R X

Akorn, Inc. N a s d a q : A K R X Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our

More information

July Bayt.com Happiness Survey in Middle East and North Africa

July Bayt.com Happiness Survey in Middle East and North Africa July 2013 Bayt.com Happiness Survey in Middle East and North Africa Objective The research was conducted to understand the current level of happiness and satisfaction in the MENA region. The key information

More information

Laboratorios Farmacéuticos ROVI

Laboratorios Farmacéuticos ROVI Laboratorios Farmacéuticos ROVI Becat on track; guidance uplifted Q3 results Pharma & biotech Laboratorios Farmacéuticos ROVI (ROVI) has reported 9M18 operating revenue of 218.9m (+7.6% y-o-y), driven

More information

This presentation is not an offer or invitation to subscribe for or purchase any securities.

This presentation is not an offer or invitation to subscribe for or purchase any securities. Disclaimer This presentation is not an offer or invitation to subscribe for or purchase any securities. No warranty is given as to the accuracy or completeness of the information in this presentation.

More information

Bayt.com Middle East Consumer Confidence Index. September 2016

Bayt.com Middle East Consumer Confidence Index. September 2016 Bayt.com Middle East Consumer Confidence Index September 2016 Section 1 PROJECT BACKGROUND Objectives To understand perceptions and attitudes of consumers in the Middle East regarding the economy of their

More information

Investment Development Authority of Lebanon Arab Spanish Investment Forum 2011

Investment Development Authority of Lebanon Arab Spanish Investment Forum 2011 Investment Development Authority of Lebanon Arab Spanish Investment Forum 2011 Wednesday October 26 th Headlines 1. ABOUT LEBANON 2. CURRENT TRENDS IN SPANISH LEBANESE TRADE 3. SPANISH COMPANIES AND LEBANON

More information

ASX Announcement MAYNE PHARMA REPORTS RECORD FY14 RESULT

ASX Announcement MAYNE PHARMA REPORTS RECORD FY14 RESULT MAYNE PHARMA REPORTS RECORD FY14 RESULT 27 August 2014, Melbourne Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to release its consolidated results for the year ended 30 June 2014. The Group

More information

Agenda. Financial Review. Review of Operations. Future Plans and Strategies. Open Forum

Agenda. Financial Review. Review of Operations. Future Plans and Strategies. Open Forum 22 October 2009 1 Disclaimer The information contained in this presentation is intended solely for your personal reference. Such information is subject to change without notice, its accuracy is not guaranteed

More information

Delivering mobile connectivity in MENA: A review of mobile sector taxation and licence extension. May 2017

Delivering mobile connectivity in MENA: A review of mobile sector taxation and licence extension. May 2017 Delivering mobile connectivity in MENA: A review of mobile sector taxation and licence extension May 2017 Executive Summary The report provides an overview of the tax and fee regime applied to mobile services

More information

PAYMENT SYSTEMS IN THE ARAB COUNTRIES

PAYMENT SYSTEMS IN THE ARAB COUNTRIES PAYMENT SYSTEMS IN THE ARAB COUNTRIES -Africa- WORLD BANK CONFERENCE REDEFINING THE LANDSCAPE OF PAYMENT SYSTEMS 7-10 APRIL 2009 CAPE TOWN-SOUTH AFRICA RAMZY HAMADEH 1 PAYMENT SYSTEMS IN THE ARAB COUNTRIES

More information

The Bayt.com Middle East and North Africa Salary Survey May 2018

The Bayt.com Middle East and North Africa Salary Survey May 2018 The Bayt.com Middle East and North Africa Salary Survey 0 May 0 Objectives The research was conducted to gauge employee satisfaction with their current salaries and factors affecting thereof. The key objectives

More information

Foreign Investment Statistics

Foreign Investment Statistics 2012-2013 Released Date: May 2015 Table of Contents Introduction....4 Key Points......5 Total Stock of Foreign Investment (FI) by Economic Activity....6 Foreign Direct Investment (FDI) by Economic Activity.......8

More information

Investor Relations Presentation December 2013

Investor Relations Presentation December 2013 Investor Relations Presentation December 2013 Contents 1. QNB at a Glance 2. QNB Comparative Positioning Qatar and MENA 3. Financial Highlights as at 31 December 2013 4. Economic Overview Notes: These

More information

The Bayt.com Middle and North Africa Salary Survey May 2014

The Bayt.com Middle and North Africa Salary Survey May 2014 The Bayt.com Middle and North Africa Salary Survey 2014 May 2014 Objective The research was conducted to gauge employee satisfaction of their current salaries and factors affecting thereof. The key objectives

More information

MSCI Index Proposal for Gulf Countries. November 2005

MSCI Index Proposal for Gulf Countries. November 2005 MSCI Index Proposal for Gulf Countries November 2005 Introduction This document sets forth MSCI s proposal to create indices for the countries of the Gulf Cooperation Council (GCC). MSCI is considering

More information

THE PRIVATE SECTOR ARM OF THE ISLAMIC DEVELOPMENT BANK GROUP

THE PRIVATE SECTOR ARM OF THE ISLAMIC DEVELOPMENT BANK GROUP THE PRIVATE SECTOR ARM OF THE ISLAMIC DEVELOPMENT BANK GROUP 3rd International Conference on Foreign Investment in Albania Islamic Corporation for the Development of the Private Sector (ICD) Member of

More information

Investor Relations Presentation September 2017

Investor Relations Presentation September 2017 Investor Relations Presentation September 2017 Contents 1. QNB at a Glance 2. QNB Comparative Positioning Qatar and MEA 3. Financial Highlights as at 30 September 2017 4. Economic Overview Notes: All figures

More information

Arab Bank Group INVESTOR RELATIONS PRESENTATION. December 31, 2017

Arab Bank Group INVESTOR RELATIONS PRESENTATION. December 31, 2017 Arab Bank Group INVESTOR RELATIONS PRESENTATION December 31, 2017 1 TABLE OF CONTENTS General Information Financial Data & KPIs Credit Rating Stock Information Corporate Governance Disclaimer Appendix

More information

The MENA-OECD Investment Programme Investment in the MENA Region and the Crisis

The MENA-OECD Investment Programme Investment in the MENA Region and the Crisis The MENA-OECD Investment Programme Investment in the MENA Region and the Crisis Amman, 15 February 2010 Agenda 1. Effects of the crisis and the work of the OECD 2. Macroeconomic trends in the MENA region

More information

Bilateral agreements on investment promotion and protection

Bilateral agreements on investment promotion and protection Bilateral agreements on investment promotion and protection Country Date Signed Entry into force South Africa 26 April 2005 - Albania 30 October 1993 - Algeria 7 July 2006 - Germany 20 December 1963 6

More information

Africa & Middle East. September rd CLSA Investors Forum Sunil Kaushal Regional CEO, Africa & Middle East

Africa & Middle East. September rd CLSA Investors Forum Sunil Kaushal Regional CEO, Africa & Middle East Africa & Middle East September 2016 23 rd CLSA Investors Forum Sunil Kaushal Regional CEO, Africa & Middle East 0 Forward looking statements This document contains or incorporates by reference forward-looking

More information

Presentation. 2013/14 Annual Results. 17 September 2014

Presentation. 2013/14 Annual Results. 17 September 2014 Corporate Presentation 2013/14 Annual Results 17 September 2014 Disclaimer The information contained in this presentation is intended solely for your personal reference. Such information is subject to

More information

LEBANON WEEKLY REPORT

LEBANON WEEKLY REPORT Lebanon s major entrepreneurship weakness is in product innovation, being the ability to provide unique products or services. The country s greatest strength in entrepreneurship is found in its perception

More information

Arab Bank Group INVESTOR RELATIONS PRESENTATION. December 31, 2016

Arab Bank Group INVESTOR RELATIONS PRESENTATION. December 31, 2016 Arab Bank Group INVESTOR RELATIONS PRESENTATION December 31, 2016 1 TABLE OF CONTENTS General Information Financial Data & KPIs Credit Rating Stock Information Corporate Governance Disclaimer Appendix

More information

Middle East and North Africa Regional Economic Outlook Oil, Conflicts, and Transitions

Middle East and North Africa Regional Economic Outlook Oil, Conflicts, and Transitions Middle East and North Africa Regional Economic Outlook Oil, Conflicts, and Transitions May 5, 2015 Agenda Global Environment MENAP Oil Exporters MENAP Oil Importers Global growth remains moderate and uneven

More information

STRENGTHENING CAPITAL MARKET REGULATION AND SUPERVISION IN THE MENA REGION

STRENGTHENING CAPITAL MARKET REGULATION AND SUPERVISION IN THE MENA REGION MENA-OECD CAPITAL MARKETS TASK FORCE MEETING ON STRENGTHENING CAPITAL MARKET REGULATION AND SUPERVISION IN THE MENA REGION 22 May 2012, starting at 14.00 Rotana Beach Hotel PRECEDING THE AMF-IMF-WORLD

More information

VAT IN UAE GENERAL UNDERSTANDING.

VAT IN UAE GENERAL UNDERSTANDING. VAT IN UAE GENERAL UNDERSTANDING Introduction of VAT Value Added Tax (VAT) is an indirect tax on consumption. It applies to most goods and services. VAT is levied on business transactions, i.e. on goods

More information

Lavendon Group plc European and Middle Eastern Market Leader for Powered Access Rental

Lavendon Group plc European and Middle Eastern Market Leader for Powered Access Rental Lavendon Group plc European and Middle Eastern Market Leader for Powered Access Rental 2015 Full Year Results Presentation 25 February 2016 25 February 2016 2015 Full Year Results Agenda Overview Financial

More information

MEIC PRE-CONFERENCE SURVEY MIDDLE EAST & NORTH AFRICA MARKET ISSUES. 6 April 2014

MEIC PRE-CONFERENCE SURVEY MIDDLE EAST & NORTH AFRICA MARKET ISSUES. 6 April 2014 MEIC PRE-CONFERENCE SURVEY MIDDLE EAST & NORTH AFRICA MARKET ISSUES 6 April 2014 SURVEY RESULTS 80% EXPECT THEIR LOCAL ECONOMY TO EXPAND IN 2014, 76% EXPECT THEIR BUSINESS TO EXPAND AND 67% EXPECT THE

More information

HSBC Holdings plc Annual Results

HSBC Holdings plc Annual Results HSBC Holdings plc Forward-looking statements This presentation and subsequent discussion may contain certain forward-looking statements with respect to the financial condition, results of operations and

More information

2010 Results. Paris - March 2, 2011

2010 Results. Paris - March 2, 2011 2010 Results Paris - March 2, 2011 > Highlights of 2010 > Financial results > Strategy and outlook 2010 Results 2 2010: A Year of Acceleration Highlights of 2010 Revenue of 3,892m, up 19.1% Operating profit

More information

Zain Group Financial Results Q4 2017

Zain Group Financial Results Q4 2017 Zain Group Financial Results Q4 2017 Disclaimer Mobile Telecommunications Company KSCP Zain Group has prepared this presentation to the best of its abilities, however, no warranty or representation, express

More information

MEIC PRE-CONFERENCE SURVEY: MIDDLE EAST & NORTH AFRICA MARKET ISSUES. March 2013

MEIC PRE-CONFERENCE SURVEY: MIDDLE EAST & NORTH AFRICA MARKET ISSUES. March 2013 MEIC PRE-CONFERENCE SURVEY: MIDDLE EAST & NORTH AFRICA MARKET ISSUES March 2013 SURVEY RESULTS POLITICAL STABILITY & GOOD GOVERNANCE WOULD HAVE THE MOST POSITIVE IMPACT ON ECONOMY 60% What do you think

More information

Middle East and North Africa Regional Economic Outlook

Middle East and North Africa Regional Economic Outlook Regional Economic Outlook Morocco Algeria Tunisia Libya Lebanon Egypt Syria Iraq Iran Jordan Saudi Kuwait Arabia Bahrain Afghanistan Pakistan Mauritania Sudan Djibouti Qatar Yemen Oman United Arab Emirates

More information

The Food Travel Experts.

The Food Travel Experts. The Food Travel Experts www.foodtravelexperts.com SSP Group plc Annual Results 2016 29 November 2016 Presentation structure 1. Group highlights Kate Swann 2. Financial review Jonathan Davies 3. Business

More information

Independent auditors report to the members of Hikma Pharmaceuticals plc

Independent auditors report to the members of Hikma Pharmaceuticals plc Financial statements We continue to deliver accurate, high-quality and timely information to all stakeholders with the utmost integrity and efficiency. 113 Independent auditors report 122 Consolidated

More information

Lupin Investor Presentation Q3FY14

Lupin Investor Presentation Q3FY14 Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.

More information

The UAE has the least demanding tax system, but new data highlights post filing challenges for the region, says PwC

The UAE has the least demanding tax system, but new data highlights post filing challenges for the region, says PwC The UAE has the least demanding tax system, but new data highlights post filing challenges for the region, says PwC Qatar and the UAE currently share equal first place globally as the easiest countries

More information

2016 Preliminary Results

2016 Preliminary Results 2016 Preliminary Results 23 February 2017 Crown copyright All statements other than statements of historical fact included in this document, including, without limitation, those regarding the financial

More information

- Net sales amounted to SEK 36.1 million (26.4), an increase of SEK 9.7 million (37%) compared to the same period of last year.

- Net sales amounted to SEK 36.1 million (26.4), an increase of SEK 9.7 million (37%) compared to the same period of last year. Press Release, 22 April 2008 (10 pages) BioGaia AB Interim report 1 January 31 March 2008 (Figures in brackets refer to the same period of the previous year) - Net sales amounted to SEK 36.1 million (26.4),

More information

Lebanon Weekly Report

Lebanon Weekly Report ECONOMY World Bank forecasts Lebanon real GDP growth at 2% in 2015 and 2.5% in 2016 The World Bank said that Lebanon s economic activity continues to tick along at a modest pace despite the political dysfunctionality.

More information

Aurobindo Pharma Limited Presentation to Investors

Aurobindo Pharma Limited Presentation to Investors Aurobindo Pharma Limited Presentation to Investors February 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,

More information

NTDEC EXECUTIVE FORUM. Current Conflicts in Middle East

NTDEC EXECUTIVE FORUM. Current Conflicts in Middle East NTDEC EXECUTIVE FORUM Current Conflicts in Middle East Presented by the North Texas District Export Council October 21. 2014 By Riad SUKKAR International Business Development AMC Global Topics Conflicts

More information

Importance of financial infrastructure to increase Access to Finance

Importance of financial infrastructure to increase Access to Finance Building a high performance SME business in the MENA Region Arab Monetary Fund & International Finance Corporation Dubai, 7-8 May 2013 Importance of financial infrastructure to increase Access to Finance

More information

Arab Bank Group. Investor Relations Presentation June 30, 2016

Arab Bank Group. Investor Relations Presentation June 30, 2016 Arab Bank Group Investor Relations Presentation June 30, 2016 1 General Information Financial Data & KPIs Q2 2016 Key Performance Extracts Credit Rating Table of Contents Stock Information Corporate Governance

More information

/JordanStrategyForumJSF Jordan Strategy Forum. Amman, Jordan T: F:

/JordanStrategyForumJSF Jordan Strategy Forum. Amman, Jordan T: F: The Jordan Strategy Forum (JSF) is a not-for-profit organization, which represents a group of Jordanian private sector companies that are active in corporate and social responsibility (CSR) and in promoting

More information

Mayne Pharma Group Limited

Mayne Pharma Group Limited Mayne Pharma Group Limited HY14 Results Presentation 26 February 2014 Scott Richards, Chief Executive Officer Mark Cansdale, Group CFO Disclaimer The information provided is general in nature and is in

More information

Q4 FY16-17 EARNINGS PRESENTATION. 29 th May 2017

Q4 FY16-17 EARNINGS PRESENTATION. 29 th May 2017 Q4 FY16-17 EARNINGS PRESENTATION 29 th May 2017 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the

More information

Dr. Reddy s Laboratories Ltd Q3 FY12 Press Meet. February 03, 2012

Dr. Reddy s Laboratories Ltd Q3 FY12 Press Meet. February 03, 2012 Dr. Reddy s Laboratories Ltd Q3 FY12 Press Meet February 03, 2012 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.

More information

MENA DEALS INSIGHT 1Q 2015

MENA DEALS INSIGHT 1Q 2015 Q1 MENA DEALS INSIGHT 1Q 2015 Quarter Highlights MENA Deal Insight 1Q2015 MENA M&A to maintain healthy growth into 2015: EY UAE seen leading mergers in the Middle East region 2014 IPOs close on a positive

More information

Algeria's GDP growth is expected to stand at 3.5%, inflation at 7.5% for 2018.

Algeria's GDP growth is expected to stand at 3.5%, inflation at 7.5% for 2018. Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Public Disclosure Authorized Key Messages: MENA Economic Monitor- April 2018 Economic growth in MENA is projected

More information

Comperative DTTs of Pakistan

Comperative DTTs of Pakistan Comperative DTTs of Pakistan 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 S. No. COUNTRY CONTINENT Republic/Dem ocratic/kingdo m/sultanate P.E. BUSINESS PROFIT SHIPPING AIR TRANSPORT DIVIDEND INTEREST ROYALITIES

More information

Switzerland Economic Update QNB Group. September 2014

Switzerland Economic Update QNB Group. September 2014 Switzerland Economic Update QNB Group September 14 Switzerland Overview Switzerland s efficient capital markets, highly skilled human capital and low corporate tax rates make it the world's most competitive

More information

A broken social contract, not inequality, triggered the Arab Spring

A broken social contract, not inequality, triggered the Arab Spring A broken social contract, not inequality, triggered the Arab Spring Shanta Devarajan and Elena Ianchovichina World Bank www.brookings.edu/futuredevelopment % of population Before 2011, poverty rates in

More information

Investor Relations Presentation April 2012

Investor Relations Presentation April 2012 Investor Relations Presentation April 2012 Contents 1. QNB at a Glance 2. Qatar Banking Sector 3. Financial Highlights March 2012 4. Economic Overview 2 QNB at a Glance QNB at a Glance: Overview Overview

More information

YouGov plc. Results in line with expectations

YouGov plc. Results in line with expectations YouGov plc Solid progress in challenging market conditions Results in line with expectations Interim results to Interim results to 31 January 2010 Overview Continuing challenging period for the market

More information

NASCO KARAOGLAN FRANCE

NASCO KARAOGLAN FRANCE NASCO KARAOGLAN FRANCE NKF VALUES WHO ARE WE? NASCO GROUP NASCO FRANCE TREATY DEPARTMENT NASCO FRANCE NK France was founded in 1976 in Paris as a wholly owned subsidiary of Nasco Karaoglan Group. The Company

More information

26 MAY Boustead Singapore Limited FY2010 Financial Results Presentation

26 MAY Boustead Singapore Limited FY2010 Financial Results Presentation 26 MAY 2010 Boustead Singapore Limited FY2010 Financial Results Presentation Disclaimer This presentation contains certain statements that are not statements of historical fact such as forward-looking

More information

For personal use only

For personal use only MAYNE PHARMA ANNOUNCES ACQUISITION OF US GENERIC PRODUCT PORTFOLIO FROM TEVA AND ALLERGAN NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES 28 June 2016, Adelaide, South Australia Mayne Pharma Group

More information

2017 Full Year Results. Tuesday 21 November 2017

2017 Full Year Results. Tuesday 21 November 2017 2017 Full Year Results Tuesday 21 November 2017 Disclaimer Certain information included in the following presentation is forward looking and involves risks, assumptions and uncertainties that could cause

More information

Interim Results 17 November 2011

Interim Results 17 November 2011 Interim Results 17 November 2011 Alan Parker Executive Chairman First 100 days Considerations: Group leadership and strategy Business model, at home and abroad Customer attraction in different markets

More information

Preliminary Results 2013 Imperial Tobacco Group PLC

Preliminary Results 2013 Imperial Tobacco Group PLC Preliminary Results 2013 Imperial Tobacco Group PLC 5 November 2013 1 Disclaimer Certain statements in this document constitute or may constitute forward-looking statements. Any statement in this document

More information

2013 Interim Results. 14 August 2013

2013 Interim Results. 14 August 2013 2013 Interim Results 14 August 2013 1 This presentation contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives.

More information

Zain Group Financial Results Q3 2018

Zain Group Financial Results Q3 2018 Zain Group Financial Results Q3 2018 2 Disclaimer Mobile Telecommunications Company KSCP Zain Group has prepared this presentation to the best of its abilities, however, no warranty or representation,

More information

Indonesia Economic Update QNB Group. October 2014

Indonesia Economic Update QNB Group. October 2014 Indonesia Economic Update QNB Group October 214 Indonesia Overview The economy has enormous long-term potential based on a rich endowment of natural resources and a large population; the new Jokowi administration

More information

A Review of Intellectual Property-Related News and Developments in the Middle East and North Africa March 2013 issue 3

A Review of Intellectual Property-Related News and Developments in the Middle East and North Africa March 2013 issue 3 Bulletin A Review of Intellectual Property-Related News and Developments in the Middle East and North Africa March 2013 issue 3 NEWS: Ethiopia - New Law Comes Into Effect The long-awaited regulations implementing

More information

January March Conference Call. Georg Denoke Member of the Executive Board & CFO 4 May 2011

January March Conference Call. Georg Denoke Member of the Executive Board & CFO 4 May 2011 January March 2011 Conference Call Georg Denoke Member of the Executive Board & CFO 4 May 2011 Disclaimer This presentation contains forward-looking statements about Linde AG ( Linde ) and their respective

More information

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd Pharmaceuticals Ltd Investor Presentation January-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Nine Months Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual Safe

More information

Edita Food Industries Reports FY2018 Earnings

Edita Food Industries Reports FY2018 Earnings Edita Food Industries Reports FY2018 Earnings Edita delivers a strong 24.1% increase in FY2018 revenues to EGP 3.8 billion as volumes continue to grow along with improved profitability. EBITDA margin in

More information

KONE Financial Statements 2007 January 25, 2008 President & CEO Matti Alahuhta. KONE Corporation

KONE Financial Statements 2007 January 25, 2008 President & CEO Matti Alahuhta. KONE Corporation KONE Financial Statements 2007 January 25, 2008 President & CEO Matti Alahuhta 1 KONE Corporation Q4 High growth in orders received and operating income continued 10-12/2007 10-12/2006 Historical change

More information

Annual General Meeting July 20, 2017

Annual General Meeting July 20, 2017 Annual General Meeting July 20, 2017 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the Company's future

More information